Serveur d'exploration sur les relations entre la France et l'Australie

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).

Identifieur interne : 001365 ( PubMed/Corpus ); précédent : 001364; suivant : 001366

Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).

Auteurs : Daniel Gaudet ; Gerald F. Watts ; Jennifer G. Robinson ; Pascal Minini ; William J. Sasiela ; Jay Edelberg ; Michael J. Louie ; Frederick J. Raal

Source :

RBID : pubmed:27793396

English descriptors

Abstract

Elevated lipoprotein(a) [Lp(a)] is independently associated with increased cardiovascular risk. However, treatment options for elevated Lp(a) are limited. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, reduced low-density lipoprotein cholesterol (LDL-C) by up to 62% from baseline in phase 3 studies, with adverse event rates similar between alirocumab and controls. We evaluated the effect of alirocumab on serum Lp(a) using pooled data from the phase 3 ODYSSEY program: 4,915 patients with hypercholesterolemia from 10 phase 3 studies were included. Eight studies evaluated alirocumab 75 mg every 2 weeks (Q2W), with possible increase to 150 mg Q2W at week 12 depending on LDL-C at week 8 (75/150 mg Q2W); the other 2 studies evaluated alirocumab 150-mg Q2W from the outset. Comparators were placebo or ezetimibe. Eight studies were conducted on a background of statins, and 2 studies were carried out with no statins. Alirocumab was associated with significant reductions in Lp(a), regardless of starting dose and use of concomitant statins. At week 24, reductions from baseline were 23% to 27% with alirocumab 75/150-mg Q2W and 29% with alirocumab 150-mg Q2W (all comparisons p <0.0001 vs controls). Reductions were sustained over 78 to 104 weeks. Lp(a) reductions with alirocumab were independent of race, gender, presence of familial hypercholesterolemia, baseline Lp(a), and LDL-C concentrations, or use of statins. In conclusion, in addition to marked reduction in LDL-C, alirocumab leads to a significant and sustained lowering of Lp(a).

DOI: 10.1016/j.amjcard.2016.09.010
PubMed: 27793396

Links to Exploration step

pubmed:27793396

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).</title>
<author>
<name sortKey="Gaudet, Daniel" sort="Gaudet, Daniel" uniqKey="Gaudet D" first="Daniel" last="Gaudet">Daniel Gaudet</name>
<affiliation>
<nlm:affiliation>Department of Medicine, ECOGENE-21 Clinical and Translational Research Center and Lipidology Unit, Université de Montréal, Chicoutimi, Quebec, Canada. Electronic address: daniel.gaudet@umontreal.ca.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name>
<affiliation>
<nlm:affiliation>Lipid Disorders Clinic, Centre for Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Robinson, Jennifer G" sort="Robinson, Jennifer G" uniqKey="Robinson J" first="Jennifer G" last="Robinson">Jennifer G. Robinson</name>
<affiliation>
<nlm:affiliation>University of Iowa, Iowa City, Iowa.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Minini, Pascal" sort="Minini, Pascal" uniqKey="Minini P" first="Pascal" last="Minini">Pascal Minini</name>
<affiliation>
<nlm:affiliation>Biostatistics and Programming, Sanofi, Chilly-Mazarin, France.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Sasiela, William J" sort="Sasiela, William J" uniqKey="Sasiela W" first="William J" last="Sasiela">William J. Sasiela</name>
<affiliation>
<nlm:affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Edelberg, Jay" sort="Edelberg, Jay" uniqKey="Edelberg J" first="Jay" last="Edelberg">Jay Edelberg</name>
<affiliation>
<nlm:affiliation>Sanofi, Bridgewater, New Jersey.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Louie, Michael J" sort="Louie, Michael J" uniqKey="Louie M" first="Michael J" last="Louie">Michael J. Louie</name>
<affiliation>
<nlm:affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Raal, Frederick J" sort="Raal, Frederick J" uniqKey="Raal F" first="Frederick J" last="Raal">Frederick J. Raal</name>
<affiliation>
<nlm:affiliation>Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:27793396</idno>
<idno type="pmid">27793396</idno>
<idno type="doi">10.1016/j.amjcard.2016.09.010</idno>
<idno type="wicri:Area/PubMed/Corpus">001365</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001365</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).</title>
<author>
<name sortKey="Gaudet, Daniel" sort="Gaudet, Daniel" uniqKey="Gaudet D" first="Daniel" last="Gaudet">Daniel Gaudet</name>
<affiliation>
<nlm:affiliation>Department of Medicine, ECOGENE-21 Clinical and Translational Research Center and Lipidology Unit, Université de Montréal, Chicoutimi, Quebec, Canada. Electronic address: daniel.gaudet@umontreal.ca.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name>
<affiliation>
<nlm:affiliation>Lipid Disorders Clinic, Centre for Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Robinson, Jennifer G" sort="Robinson, Jennifer G" uniqKey="Robinson J" first="Jennifer G" last="Robinson">Jennifer G. Robinson</name>
<affiliation>
<nlm:affiliation>University of Iowa, Iowa City, Iowa.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Minini, Pascal" sort="Minini, Pascal" uniqKey="Minini P" first="Pascal" last="Minini">Pascal Minini</name>
<affiliation>
<nlm:affiliation>Biostatistics and Programming, Sanofi, Chilly-Mazarin, France.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Sasiela, William J" sort="Sasiela, William J" uniqKey="Sasiela W" first="William J" last="Sasiela">William J. Sasiela</name>
<affiliation>
<nlm:affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Edelberg, Jay" sort="Edelberg, Jay" uniqKey="Edelberg J" first="Jay" last="Edelberg">Jay Edelberg</name>
<affiliation>
<nlm:affiliation>Sanofi, Bridgewater, New Jersey.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Louie, Michael J" sort="Louie, Michael J" uniqKey="Louie M" first="Michael J" last="Louie">Michael J. Louie</name>
<affiliation>
<nlm:affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Raal, Frederick J" sort="Raal, Frederick J" uniqKey="Raal F" first="Frederick J" last="Raal">Frederick J. Raal</name>
<affiliation>
<nlm:affiliation>Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series>
<title level="j">The American journal of cardiology</title>
<idno type="eISSN">1879-1913</idno>
<imprint>
<date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antibodies, Monoclonal (therapeutic use)</term>
<term>Anticholesteremic Agents (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Endpoint Determination</term>
<term>Ezetimibe</term>
<term>Female</term>
<term>Humans</term>
<term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term>
<term>Hypercholesterolemia (drug therapy)</term>
<term>Lipoprotein(a) (drug effects)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en">
<term>Lipoprotein(a)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antibodies, Monoclonal</term>
<term>Anticholesteremic Agents</term>
<term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Hypercholesterolemia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Endpoint Determination</term>
<term>Ezetimibe</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Elevated lipoprotein(a) [Lp(a)] is independently associated with increased cardiovascular risk. However, treatment options for elevated Lp(a) are limited. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, reduced low-density lipoprotein cholesterol (LDL-C) by up to 62% from baseline in phase 3 studies, with adverse event rates similar between alirocumab and controls. We evaluated the effect of alirocumab on serum Lp(a) using pooled data from the phase 3 ODYSSEY program: 4,915 patients with hypercholesterolemia from 10 phase 3 studies were included. Eight studies evaluated alirocumab 75 mg every 2 weeks (Q2W), with possible increase to 150 mg Q2W at week 12 depending on LDL-C at week 8 (75/150 mg Q2W); the other 2 studies evaluated alirocumab 150-mg Q2W from the outset. Comparators were placebo or ezetimibe. Eight studies were conducted on a background of statins, and 2 studies were carried out with no statins. Alirocumab was associated with significant reductions in Lp(a), regardless of starting dose and use of concomitant statins. At week 24, reductions from baseline were 23% to 27% with alirocumab 75/150-mg Q2W and 29% with alirocumab 150-mg Q2W (all comparisons p <0.0001 vs controls). Reductions were sustained over 78 to 104 weeks. Lp(a) reductions with alirocumab were independent of race, gender, presence of familial hypercholesterolemia, baseline Lp(a), and LDL-C concentrations, or use of statins. In conclusion, in addition to marked reduction in LDL-C, alirocumab leads to a significant and sustained lowering of Lp(a).</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">27793396</PMID>
<DateCreated>
<Year>2016</Year>
<Month>10</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2017</Year>
<Month>05</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1879-1913</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>119</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2017</Year>
<Month>Jan</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>The American journal of cardiology</Title>
<ISOAbbreviation>Am. J. Cardiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).</ArticleTitle>
<Pagination>
<MedlinePgn>40-46</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0002-9149(16)31568-5</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjcard.2016.09.010</ELocationID>
<Abstract>
<AbstractText>Elevated lipoprotein(a) [Lp(a)] is independently associated with increased cardiovascular risk. However, treatment options for elevated Lp(a) are limited. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, reduced low-density lipoprotein cholesterol (LDL-C) by up to 62% from baseline in phase 3 studies, with adverse event rates similar between alirocumab and controls. We evaluated the effect of alirocumab on serum Lp(a) using pooled data from the phase 3 ODYSSEY program: 4,915 patients with hypercholesterolemia from 10 phase 3 studies were included. Eight studies evaluated alirocumab 75 mg every 2 weeks (Q2W), with possible increase to 150 mg Q2W at week 12 depending on LDL-C at week 8 (75/150 mg Q2W); the other 2 studies evaluated alirocumab 150-mg Q2W from the outset. Comparators were placebo or ezetimibe. Eight studies were conducted on a background of statins, and 2 studies were carried out with no statins. Alirocumab was associated with significant reductions in Lp(a), regardless of starting dose and use of concomitant statins. At week 24, reductions from baseline were 23% to 27% with alirocumab 75/150-mg Q2W and 29% with alirocumab 150-mg Q2W (all comparisons p <0.0001 vs controls). Reductions were sustained over 78 to 104 weeks. Lp(a) reductions with alirocumab were independent of race, gender, presence of familial hypercholesterolemia, baseline Lp(a), and LDL-C concentrations, or use of statins. In conclusion, in addition to marked reduction in LDL-C, alirocumab leads to a significant and sustained lowering of Lp(a).</AbstractText>
<CopyrightInformation>Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gaudet</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, ECOGENE-21 Clinical and Translational Research Center and Lipidology Unit, Université de Montréal, Chicoutimi, Quebec, Canada. Electronic address: daniel.gaudet@umontreal.ca.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Watts</LastName>
<ForeName>Gerald F</ForeName>
<Initials>GF</Initials>
<AffiliationInfo>
<Affiliation>Lipid Disorders Clinic, Centre for Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Robinson</LastName>
<ForeName>Jennifer G</ForeName>
<Initials>JG</Initials>
<AffiliationInfo>
<Affiliation>University of Iowa, Iowa City, Iowa.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Minini</LastName>
<ForeName>Pascal</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Biostatistics and Programming, Sanofi, Chilly-Mazarin, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Sasiela</LastName>
<ForeName>William J</ForeName>
<Initials>WJ</Initials>
<AffiliationInfo>
<Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Edelberg</LastName>
<ForeName>Jay</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Sanofi, Bridgewater, New Jersey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Louie</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo>
<Affiliation>Regeneron Pharmaceuticals, Inc., Tarrytown, New York.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Raal</LastName>
<ForeName>Frederick J</ForeName>
<Initials>FJ</Initials>
<AffiliationInfo>
<Affiliation>Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2016</Year>
<Month>09</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Cardiol</MedlineTA>
<NlmUniqueID>0207277</NlmUniqueID>
<ISSNLinking>0002-9149</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017270">Lipoprotein(a)</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EOR26LQQ24</RegistryNumber>
<NameOfSubstance UI="D000069438">Ezetimibe</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000924" MajorTopicYN="N">Anticholesteremic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D023381" MajorTopicYN="N">Endpoint Determination</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000069438" MajorTopicYN="N">Ezetimibe</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006937" MajorTopicYN="N">Hypercholesterolemia</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017270" MajorTopicYN="N">Lipoprotein(a)</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2016</Year>
<Month>07</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2016</Year>
<Month>09</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2016</Year>
<Month>09</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>10</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>5</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>10</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27793396</ArticleId>
<ArticleId IdType="pii">S0002-9149(16)31568-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.amjcard.2016.09.010</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001365 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001365 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:27793396
   |texte=   Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:27793396" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024